Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 856 to 870 of 2188 results for guidelines

  1. How we develop HealthTech guidance

    Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.

  2. Endoscopic sleeve gastroplasty for obesity (HTG711)

    Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.

  3. Capsule sponge tests for detection of Barrett's oesophagus and oesophageal cancer (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

  4. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  5. Diabetes: lipid-lowering therapies for secondary prevention of CVD (IND276)

    This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  6. Stakeholder registration: medical technologies

    How to register with us as a medical technologies stakeholder.

  7. Stakeholder registration: medical technologies

    How to register with us as a medical technologies stakeholder.

  8. Experience: GP services (IND288)

    This indicator covers patient experiences of GP services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  9. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.

  10. Experience: A&E (IND291)

    This indicator covers patient experiences of A&E. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  11. Experience: hospital (IND290)

    This indicator covers patient experiences of hospital. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  12. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

  13. Hip fracture: surgery on the day or day after admission (IND14)

    This indicator covers the proportion of people with hip fracture, who receive surgery on the day of, or the day after, admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG21

  14. Hypertension: confirming diagnosis with HBPM or ABPM (IND115)

    This indicator covers the percentage of patients with a new diagnosis of hypertension (diagnosed on or after 1 April 2014) which has been confirmed by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) in the 3 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM66